Covidien Ltd Completes Previously Announced Transactions

HAMILTON, Bermuda--(BUSINESS WIRE)--Covidien Ltd. (NYSE: COV, BSX: COV) today announced that one of its subsidiaries has acquired 100% ownership of Tissue Science Laboratories, a medical device company dedicated to the research, development and commercialization of tissue implant products for surgical and wound care therapies. Covidien launched a public tender offer in the United Kingdom for all of Tissue Science Laboratories outstanding shares held by UK residents on March 12, 2008.